Tinlarebant (LBS-008)
Geographic Atrophy (GA) secondary to Dry AMD
Key Facts
About Belite Bio
Belite Bio is a clinical-stage biotech focused on developing novel oral therapies for diseases of blindness and metabolism, built on its proprietary RBP4 (Retinol Binding Protein 4) intellectual property. Its lead candidate, Tinlarebant, is in multiple late-stage trials for Geographic Atrophy (GA) and Stargardt Disease type 1 (STGD1), having secured significant regulatory designations including Breakthrough Therapy and Orphan Drug status. The company's strategy leverages a single mechanistic platform across high-unmet-need ophthalmic indications before expanding into broader metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.
View full company profileAbout Belite Bio
Belite Bio is a clinical-stage biotech focused on developing novel oral therapies for diseases of blindness and metabolism, built on its proprietary RBP4 (Retinol Binding Protein 4) intellectual property. Its lead candidate, Tinlarebant, is in multiple late-stage trials for Geographic Atrophy (GA) and Stargardt Disease type 1 (STGD1), having secured significant regulatory designations including Breakthrough Therapy and Orphan Drug status. The company's strategy leverages a single mechanistic platform across high-unmet-need ophthalmic indications before expanding into broader metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.
View full company profileAbout Belite Bio
Belite Bio is a clinical-stage biotech focused on developing novel oral therapies for diseases of blindness and metabolism, built on its proprietary RBP4 (Retinol Binding Protein 4) intellectual property. Its lead candidate, Tinlarebant, is in multiple late-stage trials for Geographic Atrophy (GA) and Stargardt Disease type 1 (STGD1), having secured significant regulatory designations including Breakthrough Therapy and Orphan Drug status. The company's strategy leverages a single mechanistic platform across high-unmet-need ophthalmic indications before expanding into broader metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.
View full company profileAbout Belite Bio
Belite Bio is a clinical-stage biotech focused on developing novel oral therapies for diseases of blindness and metabolism, built on its proprietary RBP4 (Retinol Binding Protein 4) intellectual property. Its lead candidate, Tinlarebant, is in multiple late-stage trials for Geographic Atrophy (GA) and Stargardt Disease type 1 (STGD1), having secured significant regulatory designations including Breakthrough Therapy and Orphan Drug status. The company's strategy leverages a single mechanistic platform across high-unmet-need ophthalmic indications before expanding into broader metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.
View full company profile